BerGenBio - Share Issue/Capital Change 2024

BerGenBio ASA - Ex. reverse share split and change of ISIN today

Issuer name: BerGenBio ASA

Ex. date: 30 May 2024

Type of corporate action: Reverse share split

Reverse split ratio: One hundred (100) old shares give one (1) new share.

New par value per share: NOK 10

New ISIN: NO 001 3251173

New number of shares outstanding: 39,087,116

For further information, please contact:

Martin Olin, CEO, BerGenBio ASA

Rune Skeie, CFO, BerGenBio ASA

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including cancer and severe respiratory infections. The

Company is focused on its proprietary lead candidate bemcentinib a potentially

first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC

and severe respiratory infections. BerGenBio is based in Bergen, Norway with a

subsidiary in Oxford, UK. The Company is listed on the Oslo Stock Exchange

(ticker: BGBIO). For more information, visit www.bergenbio.com.

This information is published in accordance with the requirements of the

Continuing Obligations pursuant to Oslo Rule Book II.

AI assistant